The EU Commission has approved Eylea™ 8 mg, an 8 mg aflibercept (114.3 mg/ml) injectable, for treating neovascular age-related macular degeneration and diabetic macular edema-related vision loss.

Abbisko Therapeutics entered into an exclusive license deal with Merck, Germany, for its CSF-1R inhibitor, Pimicotinib (ABSK021).

Bayer announced positive early results from Phase III OASIS 1 and 2 trials, where the experimental drug elinzanetant outperformed placebo.

To eliminate variability in lab results due to different instruments and technicians across centers, all blood or urine samples from the multicenter trial are analyzed and reported by a single lab.

Curevo Vaccine has reported its second-phase study for Amezosvatein, This advanced shingles immunization demonstrates effectiveness against Shingrix in direct comparison.

On Jan 2, 2024, MediLink Therapeutics and Roche entered a global deal to develop YL211, an ADC targeting c-MET for solid tumors.

OKYO Pharma Corporation has disclosed that OK-101 has met its primary efficacy benchmarks in Phase 2 human trials, demonstrating statistical relevance in treating dry eye condition.

Laboratory tests are often part of the safety assessment in clinical trials of unlisted drugs, and blood samples are used for clinical biochemistry and blood.

Novartis' Scemblix® outperforms traditional therapy in achieving significant molecular remission in a Phase III study involving newly diagnosed chronic myeloid leukemia patients.

On Dec 20, 2023, Hansoh Pharma and GSK unveiled an exclusive deal for the ADC new drug HS-20093, a Hansoh innovation.

Caliway Reveals US FDA Approval for Phase II Trial Application of CBL-514, a Sham-Controlled Study Aiming to Address Dercum's Syndrome.

Adverse event (AE) refers to any adverse event that may occur to the subject in the clinical trial and may be related to the trial treatment and trial treatment.